Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Other Non Operating Income: 2019-2024

Historic Other Non Operating Income for Lyell Immunopharma (LYEL) over the last 6 years, with Dec 2024 value amounting to $4.7 million.

  • Lyell Immunopharma's Other Non Operating Income fell 11200.00% to -$4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 1949.04%. This contributed to the annual value of $4.7 million for FY2024, which is 154.28% up from last year.
  • According to the latest figures from FY2024, Lyell Immunopharma's Other Non Operating Income is $4.7 million, which was up 154.28% from $1.8 million recorded in FY2023.
  • In the past 5 years, Lyell Immunopharma's Other Non Operating Income ranged from a high of $4.7 million in FY2024 and a low of -$161,000 during FY2021.
  • Over the past 3 years, Lyell Immunopharma's median Other Non Operating Income value was $1.9 million (recorded in 2022), while the average stood at $2.8 million.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first tumbled by 110.55% in 2021, then soared by 1,272.05% in 2022.
  • Lyell Immunopharma's Other Non Operating Income (Yearly) stood at $1.5 million in 2020, then tumbled by 110.55% to -$161,000 in 2021, then soared by 1,272.05% to $1.9 million in 2022, then fell by 2.17% to $1.8 million in 2023, then skyrocketed by 154.28% to $4.7 million in 2024.